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Abstract
The compounds reducing tumor cell viability and disrupting DNA topoisomerase reactions have been widely used in
anticancer drug development. Ellipticine (5,11-dimethyl-6H-pyrido[4,3-b]carbazole) is a potent intercalating agent that
interferes with nucleic acid processing through interaction with DNA topoisomerase II. Although ellipticine is a well-
characterized compound, it is not a widely-accepted drug due to the adverse effects detected upon administration. We have
previously reported two novel ellipticine derivatives, N-methyl-5-demethyl ellipticine (ET-1) and 2-methyl-N-methyl-5-
demethyl ellipticinium iodide (ET-2) as potent compounds targeting DNA topoisomerase II. This study covers an extended
synthesis, characterization, and activity data for five new salts of N-methyl 5-demetyl ellipticine (Z-1, Z-2, Z-4, Z-5 and Z-6)
having several organic halides and their effects on human topoisomerase II enzymes. Moreover, combined in silico studies
were conducted for better understanding of modes of action of studied molecules at the binding pocket of target. Our results
showed that three of the derivatives (Z-1, Z-2, and Z-6) have considerable effect on the catalytic activity of human
topoisomerase II implying the influence of alkyl groups added to the parental structure of ellipticine.
Keywords DNA topoisomerase II ● Ellipticine derivatives ● Anticancer drugs
Introduction
DNA topoisomerases play fundamental roles in overcoming
topological problems of DNA by introducing transient
breaks in the duplex during replication, transcription,
recombination, and chromosomal segregation (Wang 1971).
Given that the inherent functions of topoisomerases are
crucial for genomic integrity, the interfere with these
enzymes or generating enzyme-mediated DNA damage is
an effective strategy in development of chemotherapeutic
agents (Coban et al. 2008; Gul et al. 2009; Senarisoy et al.
2013; Ashley and Osheroff 2014; Ketron and Osheroff
2014; Zupkó et al. 2014; Vann et al. 2016a, 2016b; Delgado
et al. 2018).
Topoisomerase targeting agents act primarily in two
ways: Topoisomerase poisons stabilize the transient phos-
photyrosine covalent bond between the enzyme–DNA
complexes and kill the cells by increasing the levels of
truncated-DNA covalent intermediates (Champoux 2001;
Topcu 2001). Alternatively, topoisomerase inhibitors act by
disrupting the essential catalytic functions of the enzymes. It
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has also been shown that catalytic inhibitors affect various
stages of the catalytic cycle of topoisomerase II, including
the cleavage of DNA while some compounds manifest both
DNA breakage patterns as well as enzyme inhibition
(Topcu 2001).
The natural product ellipticine (5,11-dimethyl-6H-pyr-
ido-[4,3-b]carbazole) is one of the carbazole alkaloids with
a potent anticancer activity. Several key mechanisms of
action, including DNA intercalation and topoisomerase II
inhibition, bio-oxidation, adduct formation, mitochondrial
membrane modulation, inhibition of p53 and interaction
with kinases such as c-Kit and AKT contribute to the
anticancer activity of ellipticine (Vann et al. 2016b; Garbett
and Graves 2004; Kuo et al. 2005; Thompson et al. 2008;
Chikamori et al. 2010). Like several other topoisomerase-
targeting drugs, a number of adverse side effects such as
xerostomia, weight loss, hemolysis, and renal toxicity are
also associated with ellipticine administration mostly due to
its cytochrome P450 (CYP)- and/or peroxidase-mediated
activation yielding covalent DNA adducts (Rouëssé et al.
1993; Lichota and Gwozdzinski 2018). Therefore, over the
last years, obtaining new natural or synthetic derivatives to
replace the known topoisomerase-targeting compounds
gained a significant attention.
Several derivatives of ellipticine have been investigated
(Moody et al. 2007; Miller et al. 2012; Deane et al. 2013;
Iacopetta et al. 2017). We previously reported two novel
ellipticine derivatives, N-methyl-5-demethyl ellipticine and
2-methyl-N-methyl-5-demethyl ellipticinium iodide that
both were potent topoisomerase II-targeting compounds
(Vann et al. 2016b). We now synthesized and characterized
five new derivatives of ellipticine having alkyl groups of
different lengths with increased carbon number (Z-1 and Z-
2) and substituted alkyl groups (cyanoalkyl) (Z-4 and Z-5)
as well as a derivative with an inserted amide alkyl group
(Z-6). We monitored their effect on tumor cell growth and




We investigated side chain substituent effect at the N-2
position in order to increase the solubility and activity of
the compounds. The salts of N-methyl 5-demetyl ellipti-
cine were synthesized using N-methyl 5-demetyl ellipti-
cine and several alkyl halides, cyano alkyl halides, and
amide alkyl halide (Fig. 1). Melting points were measured
in sealed tubes using an electro thermal digital melting
point apparatus (Gallenkamp, London, UK). Fourier
transform infrared spectroscopy (FTIR) analyses using
PerkinElmer Spectrum BX-II Model FTIR spectro-
photometer were carried out for characterization of syn-
thesized molecules. The samples within KBr pellets were
measured in the range of 4000–400 cm−1. 1H-NMR and
13C-NMR spectra were obtained on a Varian AS-400
NMR spectrometer with tetramethylsilane as an internal
standard (Oxon, UK).
Synthesis of N2-methyl N-methyl 5-demethyl
ellipticine salts
N-Methyl 5-demethyl-ellipticine (2 mmol) was suspended
in dimethylformamide (5 mL), and organic halide
(2.2 mmol) was added (Vann et al. 2016b). The reaction
mixture was stirred at room temperature for 5 h, quenched
with cold ether (5 mL), and the resulting precipitate was
collected with vacuum filtration. The precipitate was
washed with cold ethanol (2.5 mL) to yield N-methyl 5-
demethyl ellipticine salts (Z-1, Z-2, Z-4, Z-5, Z-6) (Fig. 1).
N2-Ethyl N-methyl 5-demethyl ellipticinium bromide
(Z-1)
Yield: 45%; mp: 296 °C; IR (KBr) νmax: 3020 (CH), 2974
(CH), 1619 (C=N) cm−1; 1H-NMR (DMSO-d6,
400 MHz): δ 1.60 (t, 3H, +NCH2CH3), 2.97 (s, 3H, CH3),
3.74 (s, 3H, NCH3), 4.67 (q, 2H,
+NCH2CH3), 7.25
(t, 1H, J= 7.6 Hz, ArH), 7.43 (d, 1H, J= 7.6 Hz, ArH),
7.52 (d, 1H, J= 7.2 Hz, ArH), 7.73 (s, 1H, ArH), 8.09 (d,
1H, J= 7.6 Hz, ArH), 8.13 (d, 1H, J= 6.4 Hz, ArH), 8.36
(d, 1H, J= 6.4 Hz, ArH), 9.82 (s, 1H, ArH); 13C-NMR
(DMSO-d6, 100 MHz): 15.22, 16.89, 29.58, 55.74,
101.41, 109.82, 119.83, 121.34, 121.35, 124.17, 124.24,
125.55, 128.97, 131.17, 134.75, 135.05, 143.21, 145.38,
145.77.
N2-Hexyl N-methyl 5-demethyl ellipticinium
bromide (Z-2)
Yield: 52%; mp: 132 °C; IR (KBr) νmax: 3047 (CH), 2929
(CH), 1622 (C=N) cm−1; 1H-NMR (DMSO-d6, 400MHz):
δ 0.85 (t, 3H, J= 7.2 Hz, CH3), 1.24–1.45 (m, 6H, 3xCH2),
1.96–2.08 (m, 2H, CH2), 3.17 (s, 3H, CH3), 3.85 (s, 3H,
NCH3), 4.67 (t, 2H, J= 7.6 Hz, +NCH2), 7.35 (t, 1H, J=
7.6 Hz, ArH), 7.61–7.69 (m, 2H, ArH), 7.96 (s, 1H, ArH),
8.27 (d, 1H, J= 6.8 Hz, ArH), 8.31 (d, 1H, J= 8 Hz, ArH),
8.47 (d, 1H, J= 6.8 Hz, ArH), 10.02 (s, 1H, ArH); 13C-
NMR (DMSO-d6, 100MHz): 14.17, 15.08, 22.27, 25.61,
29.45, 30.96, 31.18, 60.24, 100.82, 109.66, 119.66, 121.13,
121.30, 124.02, 124.09, 125.43, 128.90, 131.31, 134.62,
134.87, 143.02, 145.22, 145.54.
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N2-Cyanomethyl N-methyl 5-demethyl ellipticinium
iodide (Z-4)
Yield: 28%; mp: 189 °C; IR (KBr) νmax: 3042 (CH), 2924
(CH), 2218 (CN), 1619 (C=N) cm−1; 1H-NMR (DMSO-d6,
400MHz): δ 3.20 (s, 3H, CH3), 3.89 (s, 3H, NCH3), 5.97 (s,
2H, +NCH2CN), 7.38–7.42 (m, 1H, ArH), 7.62–7.69 (m,
2H, ArH), 8.02 (s, 1H, ArH), 8.36 (d, 2H, J= 6.8 Hz, ArH),
8.51 (d, 1H, J= 6.8 Hz, ArH), 10.10 (s, 1H, ArH); 13C-
NMR (DMSO-d6, 100MHz): 14.09, 29.87, 62.41, 100.81,
109.52, 119.67, 120.08, 121.14, 121.32, 123.45, 124.09,




Yield: 35%; mp: 116 °C; IR (KBr) νmax: 3047 (CH), 2924
(CH), 2246 (CN), 1619 (C=N) cm−1; 1H-NMR (DMSO-d6,
400MHz): δ 2.32–2.40 (m, 2H, CH2), 2.75 (t, 2H, J=
6.8 Hz, CH2), 2.99 (s, 3H, CH3), 3.68 (s, 3H, NCH3), 4.76
(t, 2H, J= 6.8 Hz, +NCH2), 7.25 (t, 1H, J= 7.2 Hz, ArH),
7.45 (d, 1H, J= 8 Hz, ArH), 7.53 (t, 1H, J= 8 Hz, ArH),
7.74 (s, 1H, ArH), 8.10 (d, 1H, J= 8 Hz, ArH), 8.16 (d, 1H,
J= 6.8 Hz, ArH), 8.41 (d, 1H, J= 6.4 Hz, ArH), 9.99 (s,
1H, ArH); 13C-NMR (DMSO-d6, 100MHz): 14.08, 15.17,
26.79, 29.46, 58.68, 100.85, 109.69, 119.69, 120.16,
121.12, 121.29, 123.56, 124.07, 125.37, 128.86, 131.35,
134.73, 135.09, 142.99, 145.26, 146.25.
N2-(Carboxyaminoethyl) N-methyl 5-demethyl
ellipticinium bromide (Z-6)
Yield: 21%; mp: 119 °C; IR (KBr) νmax: 3058 (CH), 2935
(CH), 1673 (C=O), 1619 (C=N) cm−1; 1H-NMR (DMSO-
d6, 400MHz): δ 2.76 (t, 2H, J= 6.8 Hz, CH2), 3.20 (s, 3H,
CH3), 3.88 (s, 3H, NCH3), 4.89 (t, 2H, J= 6.8 Hz, +NCH2),
7.05 (m, 1H, ArH), 7.40 (m, 1H, ArH), 7.56 (m, 1H, ArH),
7.68 (s, 1H, NH2), 7.99 (m, 1H, ArH), 8.28 (d, 1H, J=
7.6 Hz, ArH), 8.36 (d, 1H, J= 7.6 Hz, ArH), 8.46 (d, 1H, J
Fig. 1 Ellipticine derivatives
covered in this study
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= 6.4 Hz, ArH), 10.04 (s, 1H, ArH); 13C-NMR (DMSO-d6,
100MHz): 15.51, 29.92, 36.31, 56.39, 101.58, 110.32,
120.02, 121.61, 121.82, 123.89, 124.71, 126.09, 129.21,
132.16, 135.18, 135.67, 142.76, 146.02, 147.50, 171.40.
Biology
Materials
pBR322 plazmid DNA, kinetoplast DNA (kDNA), recom-
binant human topoisomerase II were purchased from
Inspiralis (Inspiralis, Norfolk, UK). Human cervix adeno-
carcinoma (HeLa and SiHa) and breast adenocarcinoma
(MCF-7 and MDA-MB-231) cancer cell lines were pur-
chased from European Collection of Cell Cultures
(Salisbury, UK).
Cell culturing and viability assay
Cells were maintained in minimal essential medium
supplemented with 10% fetal bovine serum, 1% non-
essential amino acids and an antibiotic–antimycotic
mixture (all from Lonza Group Ltd., Basel, Switzerland).
The antiproliferative properties of the prepared analogs
were determined by means of MTT (3-(4,5-dimethyl-
thiazol-2-yl)-2,5-diphenyltetrazolium bromide, Sigma
Aldrich Ltd. (Budapest, Hungary) assay (Mosmann
1983). Briefly, near-confluent cancer cells were seeded
onto a 96-well microplate (5000/well) and, after an
overnight standing, new medium, containing the tested
compounds was added. After incubation for 72 h in
humidified air with 5% CO2 at 37 °C, the viability of the
cells were determined by the addition of 44 µL of 5 mg/
mL MTT solution. The living cells metabolized the MTT
and the produced formazan was precipitated as purple
crystals during a 4-h contact period. The medium was
next removed and the formazan was dissolved in 100 µL
of dimethylsulfoxide (DMSO) during a 60-min period of
shaking at 37 °C. Finally, the reduced MTT was assayed
at 545 nm (Stat Fax-2100, Awareness Technologies Inc.,
Palm City, FL, USA), sigmoidal concentration–response
curves were fitted to the determined data and the IC50
values were calculated by means of GraphPad Prism 4.0
(GraphPad Software, San Diego, CA, USA). All in vitro
experiments were carried out on two microplates with
five parallel wells. Stock solutions of the tested com-
pounds (10 mM) were prepared in DMSO. The highest
DMSO content of the medium (0.3%) did not have any
substantial effect on the cell proliferation. Cisplatin
(Ebewe Pharma GmbH, Unterach, Austria) was used as a
reference agent. The IC50 value is defined as the con-
centration of a compound that gives half-maximal
response.
Topoisomerase activity assays
Decatenation assays were carried out as described (Vann
et al. 2016a). Reaction mixtures contained 0.2 µg of kine-
toplast DNA (kDNA) from Crithidia fasciculata and 75 nM
and human topoisomerase II alfa in a final volume of 20 µL
of 50 mM Tris-Cl, pH 8.0, 120 mM KCl, 10 mM MgCl2,
0.5 mM ATP, and 0.5 mM dithiothreitol. Reactions were
carried out in the absence or presence of compounds for
15 min at 37 °C and terminated with 5% sarkosyl, 0.0025%
bromophenol blue, and 25% glycerol. Samples were mixed
with 2 µL of agarose loading dye (60% sucrose in 10 mM
Tris-HCl pH 7.9, 0.5% bromophenol blue, and 0.5% xylene
cyanol FF), heated for 2 min at 45 °C and subjected to
electrophoresis using 1% agarose gels in 40 mM Tris-
borate, pH 8.3 and 2 mM EDTA containing 0.5 μg/mL
ethidium bromide (Et-Br). DNA bands were visualized
under UV light and average band intensities were calculated
from three independent reactions using GeneSys program
(SynGene, Frederick MD, USA). DNA decatenation was
monitored by the conversion of large catenated networks
that remained at the origin to decatenated minicircles. One
unit of human topoisomerase II was corresponding to dec-
atenation the 200 ng of kDNA substrate for 15 min at 37 °C
in the indicated reaction buffer. Supercoil relaxing activity
of the enzyme using supercoiled plasmid DNA substrate,
pBR322 was also covered for correlation purpose (Topcu
et al. 2008).
Cleavage of Plasmid DNA
DNA cleavage assays contained 10 nM negatively super-
coiled pBR322 DNA and 150 nM human topoisomerase II
of either alfa or beta isoforms in a final volume of 20 µL of
10 mM Tris-HCl, pH 7.9, 5 mM MgCl2, 100 mM KCl,
0.1 mM EDTA, and 2.5% (v/v) glycerol (Senarisoy et al.
2013; Vann et al. 2016a). Mixtures were incubated for
6 min at 37 °C. Enzyme-DNA cleavage complexes were
trapped by the addition of 2 μL of 5% SDS followed by
2 μL of 250 mM EDTA, pH 8.0. Proteinase K (2 μL of a
0.8 mg/mL solution) was added, and samples were incu-
bated for 30 min at 45 °C to digest the enzyme. Samples
were mixed with 2 µL of agarose loading dye, heated for
2 min at 45 °C and subjected to electrophoresis as above.
DNA cleavage was monitored by the conversion of super-
coiled plasmid to linear molecules.
DNA intercalation
Human DNA topoisomerase I (0.5 U) and 300 ng of relaxed
pBR322 were incubated in 10 mM Tris-HCl, pH 7.5,
10 mM KCl, 2 mM MgCl2, 0.02 mM EDTA, 0.1 mM
dithiothreitol, and 6 µg/mL bovine serum albumin in a final
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volume of 20 µL (Vann et al. 2016b). Reactions contained
either ellipticine derivatives or Et-Br (10 µM), a well-
characterized intercalator, used as positive control. Mixtures
were incubated for 15 min at 37 °C. Following the addition
of 3 μL of stop solution (0.77% SDS 77.5 mM EDTA, pH
8.0), samples were extracted using 20 µL of phenol:
chloroform:isoamyl alcohol (25:24:1), and the aqueous
layer was mixed with 2 µL of agarose loading dye and
heated for 5 min at 45 °C. Intercalation products were
subjected to electrophoresis in a 1% agarose gel in 100 mM
Tris-borate and 2 mM EDTA. DNA bands were visualized
as described above. DNA intercalation was monitored by
the conversion of relaxed DNA to supercoiled plasmid
populations of different superhelical densities.
In silico simulations
Ligand preparation
The 2D structures of studied ligands were sketched by 2D
Sketcher program under Maestro molecular modeling
package and prepared by Ligand Preparation module (Lig-
Prep). OPLS3 force field was used to obtain low energy
conformers of ligands. Protonation states of ligands were
investigated at physiological pH by Epic module. To obtain
the lowest energy conformers of ligands, a conformational
search method was used in which all possible conforma-
tions were generated by a systematic Monte Carlo search
algorithm. The effect of slightly higher pH values (i.e., pH
8) to the protonation did not reveal any change.
Protein preparation
The crystal structure of DNA-bound human topoisomerase
II alpha was retrieved from Protein Data Bank (PDB ID:
4FM9, 25 (Wendorff et al. 2012)). The protein preparation
module of Maestro molecular modeling package was used.
The missing side chains of the protein were fixed, proto-
nation states of the amino acids were investigated at the
physiological pH 7.4 by PROPKA code. Water molecules
within the catalytic domain were kept using protein pre-
paration wizard of Maestro molecular modeling suite. Both
backbone and side chain atoms were minimized with
OPLS2005 force field to refine the protein.
Molecular docking
Molecular docking studies were performed by Glide and
GOLD docking programs (Friesner et al. 2004; Verdonk
et al. 2003). The binding interactions were calculated using
a genetic algorithm in GOLD. The following steps were
applied: (i) a population of potent binding poses at a defined
binding pocket is set up at random; (ii) each member of the
population is encoded as a “chromosome”, which contains
information about the mapping of protein−ligand interac-
tions; (iii) each chromosome is assigned a fitness score
based on its predicted binding affinity, and the chromo-
somes within the population are ranked according to fitness;
and (iv) the population of chromosomes is iteratively opti-
mized. The following genetic algorithm parameters were
used (populations size, 50; selection pressure,1.1; number
of islands, 5; migrate, 10; mutate, 95; crossover, 95; niche
size, 2; number of operations, 125,000 and search efficiency
200%). The Glide/standard precision (SP), extra precision
(XP), induced-fit docking (IFD), and quantum-polarized
ligand docking approaches implemented into the Maestro
molecular modeling package were also used. The IFD
method provides more flexibility to the binding pocket
residues. All the ligands were docked into the binding
pocket of target using Glide/SP, and then complexes with
high docking scores were forwarded to next steps. Amino
acids of complexes within the 5 Å of the docked ligands
were optimized by Prime module of Maestro. Finally, all
ligands were redocked using Glide/XP. In QPLD, initially,
Glide/XP docking was carried out to generate ten poses per
docked compound. These poses were submitted to QM
charge calculations which uses the 6-31G*/LACVP* basis
set, B3LYP density functional, and “Ultrafine” SCF
accuracy level.
Molecular dynamics (MD) simulations
MD simulations were performed using the Desmond pro-
gram with the OPLS2005 force field and RESPA integrator
(Desmond Molecular Dynamics System 2017). The com-
plex generated from top-docking pose of Glide/SP, was
immersed in orthorhombic water box and SPC solvent
models were used in the preparation of the system and
0.15M NaCl salt were added to the box in order to neu-
tralize the used systems. In all MD simulations, NPT
ensemble at 310 K with Nose–Hoover temperature coupling
(Hoover 1985) and at constant pressure of 1.01 bar via
Martyna–Tobias–Klein pressure coupling (Martyna 1994)
were used. 2.0 fs time step was used in simulations and 10-
ns MD simulations were performed both for selected
molecule Z-1 and positive control.
MetaCore/MetaDrug binary QSAR models
MetaDrug uses the property of Tanimoto Prioritization to
find the similarity between analyzed compounds and com-
pound sets in the quantitative structure–activity relation-
ships (QSAR) models based on elements found in the
structure (Metacore/Metadrug platform, Clarivate Analytics
2019). These models were prepared with a diverse set of
compounds based on experimental evidence of their
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activity/function on a certain protein of interest, and then
tested with validation sets. The accuracy of each model
depends on the number of compounds used to create it and
can be estimated by the correlation coefficient (R2) and root
mean squared error (RMSE), where a higher R2 and low
RMSE indicate higher model accuracy. The QSAR model
with the highest specificity, sensitivity, accuracy, and the
Matthews Correlation Coefficient was selected in MetaDrug
for each particular activity or toxicity tested. The prediction
of a therapeutic activity or toxic effect is calculated based
on the ChemTree ability to correlate structural descriptors to
that property using the recursive partitioning algorithm. The
ChemTree parameters that gave the best results were as
follows: path length 5, max segments 3, p value threshold
Bonnferoni 0.99, p value multiway split 0.99 and number of
random trees 50. The training set used in MetaCore/Meta-
Drug includes molecules that possess the property (posi-
tives) and chemicals that do not have such property
(negatives) in approximately equal numbers. The marketed
drugs were used if their number was greater than 100 in the
disease QSAR models; drug candidates in clinical trials and
preclinical compounds with in vivo activity have been
added to the training set. The drugs that have been anno-
tated to cause a particular toxic effect were used for the
prediction of toxic effects.
Results and discussion
The antiproliferative capacity of ellipticine and its deriva-
tives were characterized using in vitro MTT assay against
four human tumor cell lines of gynecological origin (Table 1).
Calculated IC50 values showed that ellipticine exhibited
more pronounced action compared to the reference agent,
cisplatin. The alkyl substituted analogs (Z-1 and Z-2) eli-
cited substantially higher efficacy than parental Ellipticin
against all of the utilized cell lines, followed by Z-6 while
the other congeners proved to be roughly equipotent (Z-4
and Z-5) or less active when compared to the natural
alkaloid. Ellipticine and its derivatives are aromatic
compounds with intercalating properties and used as
anticancer agents. The cytotoxicity of these compounds is
due to their effect on the topoisomerase II enzyme as well as
the hydroxyl group present in the 9 position of the pyr-
idocarbazole ring in their structure (Fig. 1). The OH group
in the ellipticine derivatives allows binding of the molecules
to the major groove on DNA and stabilize the triple com-
plex by hydrogen bonding with the enzyme (Fosse et al.
1992).
Given that vast majority of compounds, covering a
number of ellipticine derivatives effective on tumor cells
were reported to exert their effects through interfering with
topoisomerase II reactions we screened the activities of the
derivatives against DNA topoisomerase II reactions
(Senarisoy et al. 2013; Ashley and Osheroff 2014; Miller
et al. 2012; McClendon and Osheroff 2007). We therefore
employed decatenatiation, intercalation, and cleavage
assays. Decatenation assay is specific for topoisomerase II
activity. It is based on the detection of kinetoplast DNA, the
mitochondrial DNA of Crithidia fasciculata found as a
catenated network of DNA rings (Senarisoy et al. 2013). All
of the derivatives, Z-1, Z-2, Z-5, and Z-6, inhibited dec-
atenation activity of topoisomerase II at 0.2 mM con-
centration. Among the compounds, Z-1 and Z-6 (Fig. 2,
lanes 5 and 17, respectively), and Z-2 (Fig. 2, lane 8) par-
tially retained inhibition at 0.1 mM concentration. Z-1 was
found to be the most effective one in repeated densitometric
analyses by revealing an avarage IC50 of 16 μM. On the
other hand Z-2 and Z-6 gave rise to average IC50 values of
30 and 20 μM, respectively while Z-4 and Z-5 were rela-
tively less effective as the interference caused by these
compounds were not detectable upon dilution. Further
dilutions revealed disappearance of the interference on
decatenations (Fig. 2, lanes 6, 9, 12, 15 and 18 for Z1, Z3,
Z4, Z5, and Z6, respectively). These results correlated with
supercoil relaxing activity of DNA topoisomerase II using
supercoiled plasmid DNA substrate, pBR322 (data not
shown).
Although decatenation assay is a reliable method to
investigate the effect of a given compound on human
topoisomerase II, it is not solely informative about their
mode of action. We next determined if the detected activ-
ities of the compounds were because of the formation of
DNA strand breaks. We incubated the pBR322 and the alfa
and beta isoforms of the enzyme in the presence of test
compounds and terminated the reactions using SDS and
then monitored DNA breaks following Proteinase-K treat-
ment. Figure 3 shows a representative result obtained with
the compounds and the control agents, Etoposide and
mAMSA with both topoisomerase IIα and β isoforms (Fig.
3 upper and lower panels, respectively). Supercoiled
pBR322 substrate (Fig. 3, upper and lower panels lane 1)
was partially relaxed with topoisomerase IIα (Fig. 3, upper
Table 1 The IC50 values determined from cytotoxicity assays
Compounds Calculated IC50 values (µM)
HeLa SiHa MCF-7 MDA-MB-231
E 3.13 2.06 2.46 2.30
Z-1 0.06 0.63 0.91 0.77
Z-2 0.09 0.46 0.42 0.34
Z-4 54.39 19.21 4.33 27.09
Z-5 3.68 8.53 3.63 3.57
Z-6 2.42 4.92 1.72 2.99
Cisplatin 12.43 7.84 5.78 19.13
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panel, lane 2) and β (Fig. 3, lower panel, lane 2) without an
effect caused by DMSO (Fig. 3, upper and lower panels
lane 3). None of the compounds (Fig. 3, upper and lower
panels lanes 5, 6, 7, 8 and 9 for MK-1, -2, -4, -5 and -6,
respectively) and parental ellipticine (Fig. 3, upper and
lower panels lane 10) gave rise to a double strand breakage
pattern with the method we employed while both Etoposide
and mAMSA gave rise to linear DNA bands (Fig. 3, upper
and lower panels lanes 11 and 12) with a migration patter
similar linearized pBR322 (Fig. 3, upper and lower panels
lane 4).
We, then, investigated the intercalative potential of the
compounds through the shift of DNA bands from relaxed to
negatively supercoiled DNA populations. As seen in Fig. 4,
the test compounds Z1 and Z6 showed a remarkable inter-
calation (Fig. 4. Lanes 3 and 7, respectively) somewhat
similar to the intercalation of Etd-Br (Fig. 4, lane 8). The
band shifting patterns for Z2, Z4, and Z5 were neglectable
Fig. 2 Representative Topoisomerase II alfa decatenation assay in the
presence of test compounds. Agarose gel photograph indicates the
effect of the compounds Z-1, -2, -4, -5 and -6 on decatenation activity
of human topoisomerase II. Lane 1, kDNA; lane 2, kDNA with 1 u
topo II; lane 3, the same as lane 2 in the presence of DMSO, lanes 4–6,
decatenation assays in the presence of 0.2, 0.1 and 0.05 mM Z1,
respectively. The other test compounds, Z2 (lanes 7–9), Z4 (lanes
10–12), Z5 (lanes 13–15) and Z6 (lanes 16–18) were assessed at the
same concentrations
Fig. 3 A representative DNA
strand break assay in the absence
or the presence of test
compunds. The assays were
carried out either with human
topoisomerase IIα (upper panel)
or β (lower panel) isoform. The
numbers correspond to Z-1, Z-2,
Z-4, Z-5, and Z-6, respectively.
See text for detailed description
of applications
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as they were comparable with relaxed pBR322 (Fig. 4, lane
1) with human topoisomerase II (Fig. 4, lane 2).
We next used in silico simulations for five molecules
using Glide/IFD, Glide/QPLD, Glide/SP, and Glide/XP
docking protocols. Four standard inhibitors were also stu-
died for comparison. Table 2 shows top docking scores of
the test compounds at the binding pocket of human DNA
topoisomerase II alpha. Different docking algorithms were
used in docking simulations. Although GOLD Fitness and
ChemScore functions were not able to distinguish the
docking scores significantly between the studied molecules
as well as ellipticine, molecules had similar binding inter-
actions with ellipticine and they have better fitness scores
compared with positive control. Glide/SP and XP scoring
functions did not result in dramatic scoring difference
within the compounds set and reference molecules. How-
ever, all docking algorithms showed that the molecules have
similar or better docking scores than reference molecules.
Higher docking scores of compound Z-1 compared with
reference molecules were observed in IFD and QPLD
docking. It’s known that both IFD and QPLD have better
performances compared with Glide/SP and XP modules. An
induced fit protocol is used to assist with increasing the
flexibility of atoms of the target protein at the active site and
thus accurately locates the ligand with a reasonable orien-
tation. Successful docking approaches require the accurate
calculations and modeling of the partial atomic charges that
ligand is bearing. Quantum mechanics (QM) modeling may
give the highest level of docking precision when specifi-
cally, the induced charge polarization of the binding pocket
residues was considered. For the underlying consideration
regarding accuracy of docking results, QPLD, based on ab
initio charge calculations was used. The 2D and 3D ligand
interaction diagrams of Z-1 at the binding site. Crucial
amino acids were found as Glu461, Gly462, Asp463,
Leu486, Arg487, Gly488, Tyr757, His759, Gly760,
Glu761, Met762, Ser763, Leu764, and Met766. When Z1,
Z4, and Z5 docking poses were compared, it can be seen
that bioactive conformation of Z1 is totally different than Z4
and Z5 (Fig. S1, Supporting Materials).
MD simulations were performed for Z1 and ellipticine to
see the structural and dynamical profiles throughout the
simulations. (Figs. S2, S3, Supporting Materials). RMSD
and RMSF plots were compared for Z1 and ellipticine in
Fig. S2. Binding interactions analyses of Z1 showed that
especially two residues Met762 and Met766 are crucial for
ligand-target interactions.
Pharmacokinetic profiles of studied molecules Z-1, Z-2,
and Z-6 were also performed by binary QSAR models of
MetaCore/MetaDrug platform. Results showed that within
26 toxicity QSAR models, Z-1 and Z-2 showed toxicity in
only three models (AMES, Anemia, and cardiotoxicity).
Compound Z-6 showed toxicity profile only in four models
(AMES, Anemia and liver cholestasis and neurotoxicity).
However, it must be noted that three out of four results of
toxic profiles in compound Z6 were in near threshold (0.5).
Toxicity predictions were also compared with known
Fig. 4 DNA intercalation assay. Intercalation by ellipticine derivatives
was based on the detection of the band shift from relaxed to negatively
supercoiled DNA. Assays that contained only the relaxed DNA sub-
strate or relaxed DNA and topoisomerase I with no compound are
shown in lanes 1 and 2, respectively. The derivatives Z-1, Z-2, Z-4, Z-
5, and Z-6 are applied on the lanes 3–7, respectively. Strong inter-
calator agent, Et-Br is shown at the lane 8














Z-1 −12.378 −7.428 −4.766 −7.344 41.21 −5.22
Z-2 −12.337 −6.917 −5.888 −6.911 45.38 −6.14
Z-4 −11.616 −7.208 −4.491 −7.025 41.85 −5.18
Z-5 −12.521 −7.288 −5.860 −7.043 46.12 −5.21
Z-6 −12.306 −7.061 −6.293 −7.345 43.60 −4.71
Ellipticine −8.901 −6.952 −6.428 −8.420 34.54 −5.38
Ciprofloxacin −6.246 −6.431 −6.467 −6.680 NA NA
Ofloxacin −6.358 −6.523 −4.909 −7.140 NA NA
Mitonafide −5.107 −5.893 −5.010 −6.450 NA NA
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inhibitor ellipticine. Ellipticine showed toxicity in five
models (AMES, carcinogenicity in male mouse, carcino-
genicity in rat female, cardiotoxicity, and genotoxicity) out
of 26 different toxicity QSAR models (Table S1, Support-
ing Materials).
Taken together, our results showed that the com-
pounds Z1, Z2, and Z6 have significant potential as
compounds targeting human DNA topoisomerase II.
Given that the alfa and beta isoforms of human DNA
topoisomerase II is expressed in a different pattern in
normal and cancer cells, differentiating between these
two isoforms is an important aspect of topoisomerase-
targeting drug development. However, the absence of
DNA breaks in either isoform when compared to the
reference compounds revealed that ellipticine derivatives
could affect inhibition of catalytic activity rather than
stabilizing the covalent complex.
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